Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 6/20 | 0.66 |
| ▸ | CACNA1B | Q00975 | 6/20 | 0.66 |
| ▸ | CACNB1 | Q02641 | 6/20 | 0.66 |
| ▸ | CACNA1C | Q13936 | 5/20 | 0.66 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4273028 | 0.94 | CACNA2D1 (0.62) | CACNA2D1CACNA1BCACNB1CACNA1CCHRM3 | |
| SCHEMBL4273013 | 0.82 | CACNA2D1 (0.58) | CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL3394375 | 0.81 | CACNA2D1 (0.70) | CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL4270399 | 0.78 | CHRM3 (0.49) | CACNA2D1CACNA1BCACNB1CACNA1CCHRM3 | |
| SCHEMBL2792554 | 0.77 | CACNA2D1 (0.64) | CACNA2D1CACNA1BCACNB1CACNA1CCHRM3 | |
| SCHEMBL4279749 | 0.77 | CACNA2D1 (0.66) | CACNA2D1CACNA1BCACNB1CACNA1CCHRM3 | |
| SCHEMBL4279744 | 0.76 | CACNA2D1 (0.77) | CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL2797186 | 0.76 | CACNA2D1 (0.92) | CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL4281025 | 0.75 | CACNA2D1 (0.58) | CACNA2D1CACNA1BCACNB1CACNA1CCHRM3 | |
| SCHEMBL4278107 | 0.75 | KMT2A (0.60) | CACNA2D1CACNA1BCACNB1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-09-03 | — | — | US | claimed |
| EP-1976841-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2008-10-08 | — | — | EP | claimed |
| WO-2007071035-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-06-28 | — | — | WO | claimed |
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | RYR2, CACNA1E, RYR1 | CACNA2D1 45/4885CACNA1B 5/4885CACNB1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.